We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ImmunoGen Lead Drug Gets Nod for Accelerated Approval Pathway (Revised)
Read MoreHide Full Article
ImmunoGen, Inc. announced that the FDA has advised to conduct a new single-arm pivotal study, which can support accelerated approval for its lead candidate, mirvetuximab soravtansine, in ovarian cancer. We note that the FDA had recommended a new monotherapy study on the candidate in May, following the failure of phase III study – FORWARD 1.
Based on the FDA’s guidance, the company is planning to initiate a pivotal study, SORAYA, in patients with platinum-resistant ovarian cancer whose tumors express high levels of FR alpha and who have received prior treatment with Roche’s (RHHBY - Free Report) Avastin (bevacizumab). The company is expected to start enrolling patients in the SORAYA study by the next quarter, with top-line data expected to be available by mid-2021. The company is anticipating to file a regulatory application in the second half of 2021, seeking accelerated approval for mirvetuximab soravtansine, if the study is completed successfully.
Shares of ImmunoGen gained 18.8% on Dec 17 following the announcement. Investors cheered the news as a single-arm, pivotal study is likely to reduce the time to get an approval for mirvetuximab soravtansine. The company’s shares have gained 13.8% so far this year compared with the industry’s increase of 13.2%.
Please note that the company announced in March that its FORWARD 1 study failed to meet the primary endpoint of progression-free survival (“PFS”). The FORWARD 1 study evaluated the efficacy of mirvetuximab soravtansine as a single-agent therapy compared to chemotherapy for the treatment of patients with platinum-resistant ovarian cancer whose tumors express high or medium levels of FR alpha and who have received up to three prior treatment regimens. However, the overall response rate (“ORR”) for the candidate was higher tin the study compared to patients who were treated with chemotherapy.
The SORAYA study will evaluate the candidate in patients with platinum-resistant ovarian cancer whose tumors express high levels of FRα and have received up to three prior treatments, including at least one with Avastin. However, the primary endpoint of the study will be ORR instead of PFS as in FORWARD 1 study.
Meanwhile, the company stated on its third-quarter earnings call that it has met with the FDA to review the design of a phase III study – MIRASOL – which will compare mirvetuximab soravtansine head-to-head with single agent chemotherapy in platinum-resistant ovarian cancer patients with high folate receptor alpha expression. The company expects to initiate enrollment in the study by the year end. It is planning to use this study as a confirmatory study, which will support continued approval for mirvetuximab soravtansine, if it gets accelerated approval based on SORAYA study data. Top-line data from MIRASOL study is anticipated in the first half of 2022.
A phase Ib/II FORWARD II study is evaluating mirvetuximab soravtansine in combination with Avastin or Merck’s (MRK - Free Report) Keytruda for treating cancerous tumors especially with medium or high FRα expression levels.
Apart from mirvetuximab soravtansine, the company is also developing another pipeline candidate, IMGN632, in several early- to mid-stage studies as monotherapy or in combination with Celgene’s Vidaza or AbbVie (ABBV - Free Report) /Roche’s Venclexta for treating acute myeloid leukemia and other oncology indications.
Image: Bigstock
ImmunoGen Lead Drug Gets Nod for Accelerated Approval Pathway (Revised)
ImmunoGen, Inc. announced that the FDA has advised to conduct a new single-arm pivotal study, which can support accelerated approval for its lead candidate, mirvetuximab soravtansine, in ovarian cancer. We note that the FDA had recommended a new monotherapy study on the candidate in May, following the failure of phase III study – FORWARD 1.
Based on the FDA’s guidance, the company is planning to initiate a pivotal study, SORAYA, in patients with platinum-resistant ovarian cancer whose tumors express high levels of FR alpha and who have received prior treatment with Roche’s (RHHBY - Free Report) Avastin (bevacizumab). The company is expected to start enrolling patients in the SORAYA study by the next quarter, with top-line data expected to be available by mid-2021. The company is anticipating to file a regulatory application in the second half of 2021, seeking accelerated approval for mirvetuximab soravtansine, if the study is completed successfully.
Shares of ImmunoGen gained 18.8% on Dec 17 following the announcement. Investors cheered the news as a single-arm, pivotal study is likely to reduce the time to get an approval for mirvetuximab soravtansine. The company’s shares have gained 13.8% so far this year compared with the industry’s increase of 13.2%.
Please note that the company announced in March that its FORWARD 1 study failed to meet the primary endpoint of progression-free survival (“PFS”). The FORWARD 1 study evaluated the efficacy of mirvetuximab soravtansine as a single-agent therapy compared to chemotherapy for the treatment of patients with platinum-resistant ovarian cancer whose tumors express high or medium levels of FR alpha and who have received up to three prior treatment regimens. However, the overall response rate (“ORR”) for the candidate was higher tin the study compared to patients who were treated with chemotherapy.
The SORAYA study will evaluate the candidate in patients with platinum-resistant ovarian cancer whose tumors express high levels of FRα and have received up to three prior treatments, including at least one with Avastin. However, the primary endpoint of the study will be ORR instead of PFS as in FORWARD 1 study.
Meanwhile, the company stated on its third-quarter earnings call that it has met with the FDA to review the design of a phase III study – MIRASOL – which will compare mirvetuximab soravtansine head-to-head with single agent chemotherapy in platinum-resistant ovarian cancer patients with high folate receptor alpha expression. The company expects to initiate enrollment in the study by the year end. It is planning to use this study as a confirmatory study, which will support continued approval for mirvetuximab soravtansine, if it gets accelerated approval based on SORAYA study data. Top-line data from MIRASOL study is anticipated in the first half of 2022.
A phase Ib/II FORWARD II study is evaluating mirvetuximab soravtansine in combination with Avastin or Merck’s (MRK - Free Report) Keytruda for treating cancerous tumors especially with medium or high FRα expression levels.
Apart from mirvetuximab soravtansine, the company is also developing another pipeline candidate, IMGN632, in several early- to mid-stage studies as monotherapy or in combination with Celgene’s Vidaza or AbbVie (ABBV - Free Report) /Roche’s Venclexta for treating acute myeloid leukemia and other oncology indications.
ImmunoGen, Inc. Price
ImmunoGen, Inc. price | ImmunoGen, Inc. Quote
Zacks Rank
ImmunoGen currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
(We are reissuing this article to correct a mistake. The earlier article on this topic, issued on December 18, 2019, should no longer be relied upon.)